Medpace Holdings Business Summary

Medpace Holdings, Inc. (MEDP) operates as a scientifically-driven, global full-service contract research organization (CRO) providing Phase I-IV clinical development services. The company generates revenue through a fee-for-service model, primarily executing long-term contracts for clinical trial management, laboratory services, and regulatory consulting, supplemented by the reimbursement of out-of-pocket expenses. Its primary business segments are categorized by therapeutic expertise, with significant concentrations in oncology, metabolic disease, cardiology, and the central nervous system. Medpace distinguishes itself in the market as a premium mid-sized player that specifically targets small-to-mid-sized biotechnology firms, a niche often underserved by larger competitors. Its direct rivals include industry titans such as IQVIA, PPD (a part of Thermo Fisher Scientific), Parexel, and Fortrea; however, Medpace maintains a competitive edge through its highly integrated, "high-science" operational model and superior EBITDA margins relative to the industry average. The company was founded in 1992 by Dr. August J. Troendle, who continues to serve as Chairman and CEO, bringing a pedigree that includes tenure as a Medical Review Officer at the FDA and a clinical development manager at Sandoz (Novartis). The leadership team is further anchored by President Jesse Geiger, a CPA who previously held executive roles at SENCORP and Cincinnati Bell, and CFO Kevin Brady, who joined from Myriad Genetics and Procter & Gamble. Technical and medical oversight is led by Chief Information Officer Brandon Ebken and Chief Medical Officer Reinilde Heyrman. Medpace is characterized by high institutional ownership, with major stakes held by BlackRock, Vanguard, and State Street, while its Board of Directors features seasoned industry figures such as Lead Independent Director Fred Davenport and Dr. Dani Zander. Dr. Troendle remains a significant individual shareholder, maintaining approximately 19% of the company's equity as of early 2026.